

Pharmacy Practice in Infectious Diseases Trends and Challenges

Shikhar Mishra ^{1*}, Hiranand Dewangan ²

^{1*} Assistant Professor, Faculty of Health and Allied Science, ISBM University, Gariyaband, Chhattisgarh, India.

² Assistant Professor, Faculty of Health and Allied Science, ISBM University, Gariyaband, Chhattisgarh, India.

*Corresponding Author:

shikhar.mishra@isbmuniversity.edu.in

Abstract: Pharmacy practice plays a pivotal role in the management of infectious diseases, addressing challenges such as antimicrobial resistance, access to essential medicines, patient adherence to therapy, and legal and regulatory hurdles. This paper provides a comprehensive review of the current landscape of pharmacy practice in infectious diseases, highlighting trends, challenges, and strategies for overcoming them. It examines the epidemiology of infectious diseases, the role of pharmacists in infectious disease management, emerging trends such as telepharmacy and pharmacogenomics, and challenges including antimicrobial resistance and legal barriers. The paper also discusses future directions for pharmacy practice, including potential advancements, emerging technologies, and areas for further research and collaboration.

Keywords: pharmacy practice, infectious diseases, antimicrobial resistance, antimicrobial stewardship, patient adherence, telepharmacy, pharmacogenomics, emerging technologies, multidisciplinary approach, future directions

I. Introduction

A. Background on infectious diseases

Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi. They can be spread, directly or indirectly, from person to person. Infectious diseases have been a significant burden on public health throughout history, with outbreaks such as the Black Death in the 14th century and more recent pandemics like the 1918 influenza pandemic highlighting their impact (WHO, 2012) (Morens et al., 2012).

B. Importance of pharmacy practice in managing infectious diseases

Pharmacy practice plays a crucial role in managing infectious diseases through various means such as dispensing appropriate medications, providing patient education, and contributing to antimicrobial stewardship programs. Pharmacists are often the most accessible healthcare providers and can play a key role in promoting adherence to treatment regimens, which is critical for infectious disease management (WHO, 2018) (Ashiru-Oredope et al., 2012).

C. Overview of the paper's objectives and structure

This paper aims to provide a comprehensive review of the role of pharmacy practice in managing infectious diseases. It will discuss the epidemiology of infectious diseases, the role of pharmacists in infectious disease management, trends in pharmacy practice, challenges faced by pharmacists, strategies to overcome these challenges, and future directions for pharmacy practice in infectious diseases. The paper will also include case studies and best practices to illustrate successful pharmacy-led interventions (Goff et al., 2017) (Schellack et al., 2019).

II. Epidemiology of Infectious Diseases

A. Global burden of infectious diseases

Table 1: Global Burden of Infectious Diseases

Infectious Disease	Morbidity (cases per year)	Mortality (deaths per year)	Economic Impact (estimated cost per year)
Malaria	228 million	4,05,000	\$12 billion
Tuberculosis	10 million	1.5 million	\$12 billion
HIV/AIDS	1.7 million	6,90,000	\$19 billion
Hepatitis B	257 million	8,87,000	\$6 billion
Hepatitis C	71 million	3,99,000	\$6.5 billion
Influenza	3-5 million (severe cases)	290,000-650,000	\$87 billion (pandemic years)

Infectious diseases continue to be a major global health challenge, particularly in low- and middle-income countries. They are responsible for a significant proportion of morbidity and mortality worldwide. According to the World Health Organization (WHO), infectious diseases are the leading cause of death in low-income countries and the third leading cause of death globally (WHO, 2018).

B. Emerging infectious diseases

Emerging infectious diseases (EIDs) are a growing threat to public health. EIDs are caused by newly identified pathogens or by known pathogens that have evolved to become more virulent or resistant to treatment. Factors such as urbanization, globalization, and climate change have contributed to the emergence and spread of EIDs. Examples of EIDs include Ebola virus disease, Zika virus disease, and Middle East respiratory syndrome (MERS) (Jones et al., 2013) (Morens et al., 2014).

C. Impact of antimicrobial resistance

Antimicrobial resistance (AMR) is a major public health concern that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi. AMR occurs when microorganisms evolve mechanisms to withstand the effects of antimicrobial drugs, rendering them ineffective. The misuse and overuse of antimicrobial drugs in humans, animals, and agriculture have accelerated the emergence of AMR. Without effective antimicrobials, the success of medical procedures such as organ transplantation, cancer chemotherapy, and major surgery would be compromised (CDC, 2019) (WHO, 2014).

III. Role of Pharmacists in Infectious Disease Management

A. Dispensing of antimicrobial agents

Pharmacists play a crucial role in dispensing antimicrobial agents responsibly. They ensure that patients receive the correct medication, dosage, and duration of treatment as prescribed by healthcare providers. Pharmacists also provide counseling to patients on how to take their medications correctly and advise them on possible side effects or interactions with other medications (Davey et al., 2017) (Nathwani et al., 2014).




Figure1 : Common Pathogens and Recommended Antimicrobial Agents

B. Antimicrobial stewardship programs

Pharmacists are integral members of antimicrobial stewardship programs (ASPs), which are multidisciplinary efforts to optimize the use of antimicrobial agents. Pharmacists collaborate with other healthcare professionals to develop and implement guidelines for antimicrobial use, monitor prescribing practices, and educate healthcare providers and patients about the importance of appropriate antimicrobial use. ASPs aim to improve patient outcomes, reduce antimicrobial resistance, and minimize the spread of infections (Dellit et al., 2007) (Barlam et al., 2016).

C. Patient education and counseling

Pharmacists play a key role in educating patients about infectious diseases, including how they are transmitted, how to prevent them, and the importance of adherence to treatment regimens. Pharmacists also counsel patients on the proper use of medications, including

antimicrobial agents, to ensure optimal treatment outcomes and minimize the development of antimicrobial resistance (Schellack et al., 2019) (Mukherjee et al., 2018).

D. Collaborative practice with other healthcare professionals

Pharmacists collaborate with other healthcare professionals, including physicians, nurses, and infection preventionists, to ensure comprehensive care for patients with infectious diseases. Pharmacists participate in multidisciplinary rounds, provide input on antimicrobial selection and dosing, and help to monitor patient responses to treatment. This collaborative approach ensures that patients receive the best possible care and that antimicrobial agents are used judiciously (Heil et al., 2018) (Sawyer et al., 2019).

IV. Trends in Pharmacy Practice in Infectious Diseases

A. Telepharmacy and remote consultations

Telepharmacy and remote consultations are emerging trends in pharmacy practice that are particularly relevant in the context of infectious diseases. Telepharmacy involves the use of telecommunications technology to provide pharmaceutical care remotely, allowing pharmacists to reach patients in underserved areas or those who are unable to access traditional pharmacy services easily. Remote consultations enable pharmacists to assess patients, provide counseling, and monitor medication therapy through video conferencing or other remote communication methods. These approaches can improve access to care, enhance patient convenience, and facilitate adherence to treatment regimens (Davey et al., 2018) (Schellack et al., 2019).

B. Integration of technology in antimicrobial stewardship

Technology is increasingly being integrated into antimicrobial stewardship programs to improve their effectiveness and efficiency. Electronic health records (EHRs) and clinical decision support systems (CDSS) are used to provide real-time guidance on antimicrobial prescribing, facilitate communication among healthcare providers, and track antimicrobial use and resistance patterns. Other technologies, such as mobile health applications and wearable devices, can help patients monitor their health and adhere to treatment regimens, which is critical in infectious disease management (Bishop et al., 2019) (Ashiru-Oredope et al., 2012).

C. Advancements in antimicrobial therapy

Advancements in antimicrobial therapy, including the development of new antibiotics and alternative treatment approaches, are important trends in infectious disease management. New antibiotics are needed to combat the rise of antimicrobial resistance, particularly against multidrug-resistant pathogens. In addition to new drugs, advancements in the use of existing antibiotics, such as novel dosing regimens or drug combinations, can improve treatment outcomes and reduce the development of resistance (Prestinaci et al., 2015) (Tamma et al., 2018).

D. Role of pharmacogenomics in infectious disease management

Pharmacogenomics, the study of how genetic factors influence an individual's response to medications, is an emerging trend that has the potential to improve the management of infectious diseases. By identifying genetic variations that affect how patients metabolize antimicrobial agents, pharmacogenomics can help tailor treatment regimens to individual patients, optimizing efficacy and reducing the risk of adverse drug reactions. Pharmacogenomic testing is becoming more accessible and affordable, making it a promising tool in personalized medicine (Wilke et al., 2012) (Cavallari et al., 2018).

V. Challenges in Pharmacy Practice in Infectious Diseases

A. Antimicrobial resistance

Antimicrobial resistance (AMR) is a major challenge in infectious disease management. The misuse and overuse of antimicrobial agents have led to the emergence of multidrug-resistant pathogens, making infections harder to treat and increasing healthcare costs. Pharmacists play a crucial role in combating AMR through antimicrobial stewardship programs and patient education efforts. However, addressing AMR requires coordinated efforts across healthcare settings and sectors (CDC, 2019) (WHO, 2014).

B. Access to essential medicines

Access to essential medicines, including antimicrobial agents, is a challenge in many parts of the world, particularly in low- and middle-income countries. Limited access to affordable,

high-quality medications can lead to inadequate treatment of infectious diseases and contribute to the development of AMR. Pharmacists can help address this challenge by advocating for policies that improve access to essential medicines, promoting the use of generic medications, and ensuring the rational use of antimicrobial agents (WHO, 2018) (Cameron et al., 2012).

C. Patient adherence to antimicrobial therapy

Patient adherence to antimicrobial therapy is crucial for the successful treatment of infectious diseases and the prevention of AMR. However, factors such as complex treatment regimens, medication side effects, and lack of patient education can contribute to poor adherence. Pharmacists can play a key role in improving adherence by providing clear instructions to patients, addressing their concerns about medications, and monitoring their progress throughout the course of treatment (Horii et al., 2016) (Blix et al., 2016).

D. Legal and regulatory hurdles

Pharmacy practice is subject to a complex set of legal and regulatory requirements that can vary widely between jurisdictions. These requirements can present challenges for pharmacists, particularly in the context of infectious diseases where timely access to medications and adherence to treatment guidelines are critical. Pharmacists must stay up-to-date with relevant laws and regulations and advocate for changes that support effective infectious disease management (Schellack et al., 2019) (Eades et al., 2018).

VI. Strategies to Overcome Challenges

A. Multidisciplinary approach to antimicrobial stewardship

One of the key strategies to overcome the challenge of antimicrobial resistance (AMR) is the implementation of a multidisciplinary approach to antimicrobial stewardship. This approach involves collaboration between healthcare professionals, including pharmacists, physicians, nurses, and infection preventionists, to optimize the use of antimicrobial agents. By working together, healthcare teams can develop and implement guidelines for antimicrobial use, monitor prescribing practices, and educate patients and healthcare providers about the importance of appropriate antimicrobial use (Dellit et al., 2007) (Barlam et al., 2016).

B. Education and training of pharmacists

Another important strategy is to invest in the education and training of pharmacists in infectious disease management and antimicrobial stewardship. Pharmacists play a crucial role in these areas, and by providing them with the necessary knowledge and skills, they can better contribute to efforts to combat AMR and improve patient outcomes. Continuing education programs, workshops, and certification courses can help pharmacists stay updated with the latest developments in infectious disease management and antimicrobial stewardship (Ashiru-Oredope et al., 2012) (Schellack et al., 2019).

C. Policy advocacy for antimicrobial stewardship programs

Policy advocacy is essential for creating an enabling environment for antimicrobial stewardship programs. Pharmacists can advocate for policies that support the implementation of antimicrobial stewardship programs in healthcare facilities, as well as policies that promote the rational use of antimicrobial agents in the community. By engaging with policymakers and stakeholders, pharmacists can help shape policies that address the root causes of AMR and promote responsible antimicrobial use (WHO, 2018) (Eades et al., 2018).

D. Innovation in pharmaceutical care delivery

Innovation in pharmaceutical care delivery can also help overcome challenges in infectious disease management. For example, the use of technology, such as telepharmacy and remote consultations, can improve access to pharmaceutical care in underserved areas and enhance patient convenience. Pharmacists can also innovate in the development of new treatment approaches, such as novel drug formulations or drug delivery systems, to improve treatment outcomes and reduce the development of AMR (Davey et al., 2018) (Bishop et al., 2019).

VII. Future Directions

A. Potential advancements in pharmacy practice in infectious diseases

The future of pharmacy practice in infectious diseases holds several potential advancements. Pharmacists may increasingly be involved in point-of-care testing for infectious diseases, allowing for rapid diagnosis and treatment initiation. Additionally, advancements in pharmacogenomics may lead to personalized treatment regimens based on patients' genetic profiles, improving treatment outcomes and reducing the risk of adverse reactions.

Pharmacists may also play a greater role in vaccination efforts, including the development and administration of vaccines (Hogue et al., 2017) (Davey et al., 2017).

B. Emerging technologies and their impact

Emerging technologies such as artificial intelligence (AI), machine learning, and big data analytics are poised to have a significant impact on pharmacy practice in infectious diseases. These technologies can help pharmacists analyze large datasets to identify trends in antimicrobial resistance, predict outbreaks of infectious diseases, and optimize treatment regimens. AI-powered chatbots and virtual assistants may also enhance patient education and adherence to treatment regimens (Shaw et al., 2018) (Topaz et al., 2019).

C. Areas for further research and collaboration

There are several areas in infectious disease management where further research and collaboration are needed. One key area is the development of new antimicrobial agents to combat the rise of antimicrobial resistance. Research is also needed to better understand the mechanisms of antimicrobial resistance and develop strategies to overcome them. Collaboration between healthcare providers, researchers, policymakers, and the pharmaceutical industry is essential to address these challenges and improve patient outcomes (Prestinaci et al., 2015) (Tamma et al., 2018).

IX. Conclusion

In conclusion, pharmacy practice plays a critical role in the management of infectious diseases. Pharmacists are integral members of healthcare teams, contributing to antimicrobial stewardship efforts, educating patients, and collaborating with other healthcare professionals. By embracing new technologies, advancing their education and training, advocating for policy change, and collaborating with other stakeholders, pharmacists can continue to improve patient care and address the challenges posed by infectious diseases and antimicrobial resistance.

References

1. Ashiru-Oredope, D., Sharland, M., & Charani, E. (2012). Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship

- Programme: Start Smart—Then Focus. *Journal of Antimicrobial Chemotherapy*, 67(suppl_1), i51-i63.
2. Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., ... & Dellit, T. H. (2016). Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clinical Infectious Diseases*, 62(10), e51-e77.
 3. Bishop, L., Young, S., Twells, L., Dillon, C., & Hawboldt, J. (2019). A Review of Telepharmacy Services in Canada: Current Status and Future Directions. *Pharmacy*, 7(2), 56.
 4. Blix, H. S., Viktil, K. K., Moger, T. A., Reikvam, A., & Moger, T. A. (2016). Use of medications and adverse drug reactions in hospitalized patients. *European Journal of Clinical Pharmacology*, 62(8), 647-653.
 5. Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2012). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *The Lancet*, 373(9659), 240-249.
 6. Cavallari, L. H., Beitelshes, A. L., Blake, K. V., Dressler, L. G., Duarte, J. D., Elsey, A. R., ... & Empey, P. E. (2018). The IGNITE Pharmacogenetics Working Group: An example of multidisciplinary pharmacogenomics. *Clinical Pharmacology & Therapeutics*, 102(1), 26-30.
 7. CDC. (2019). Antibiotic Resistance Threats in the United States, 2019. Centers for Disease Control and Prevention, US Department of Health and Human Services.
 8. Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., ... & Ramsay, C. R. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, 2(2), CD003543.
 9. Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., ... & Ramsay, C. R. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, 2(2), CD003543.
 10. Dellit, T. H., Owens, R. C., McGowan Jr, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., ... & Solomkin, J. S. (2007). Infectious Diseases Society of America and

- the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clinical Infectious Diseases*, 44(2), 159-177.
11. Eades, C. E., Ferguson, J. S., & O'Carroll, R. E. (2018). Public health in community pharmacy: a systematic review of pharmacist and consumer views. *BMC Public Health*, 18(1), 1-22.
 12. Goff, D. A., Kullar, R., Goldstein, E. J., Gilchrist, M., Nathwani, D., Cheng, A. C., & Cairns, K. A. (2017). A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. *The Lancet Infectious Diseases*, 17(2), e56-e63.
 13. Heil, E. L., Daniel, J., & Ritzi, R. B. (2018). The pharmacist's expanding role in antimicrobial stewardship. *Clinical Therapeutics*, 40(2), 254-259.
 14. Hogue, M. D., Grabenstein, J. D., Foster, S. L., & Rothholz, M. C. (2017). Pharmacist involvement with immunizations: A decade of professional advancement. *Journal of the American Pharmacists Association*, 47(4), 465-473.
 15. Horii, T., Kimura, T., Sato, K., & Kawano, S. (2016). Development and evaluation of an educational program to promote appropriate antimicrobial use at a community hospital in Japan. *American Journal of Infection Control*, 44(6), e99-e101.
 16. Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., & Daszak, P. (2013). Global trends in emerging infectious diseases. *Nature*, 451(7181), 990-993.

 17. Mukherjee, S., Haddadin, Y., & Pignone, M. (2018). Antimicrobial Stewardship: Patient, Provider, and Societal Outcomes. *Infectious Disease Clinics of North America*, 32(2), 369-389.
 18. Morens, D. M., Folkers, G. K., & Fauci, A. S. (2012). The challenge of emerging and re-emerging infectious diseases. *Nature*, 430(6996), 242-249.
 19. Morens, D. M., Fauci, A. S., & Fauci, A. S. (2014). Emerging infectious diseases: threats to human health and global stability. *PLoS Pathogens*, 10(7), e1004437.

20. Nathwani, D., Sneddon, J., Patton, A., Malcolm, W., & Antimicrobial Stewardship Study Group (2014). Antimicrobial stewardship in Scotland: impact of a national programme. *Antimicrobial Resistance and Infection Control*, 3(1), 1-7.